Publication | Closed Access

Safety, tolerability, and immunogenicity of a 21-valent pneumococcal conjugate vaccine, V116, in healthy adults: phase 1/2, randomised, double-blind, active comparator-controlled, multicentre, US-based trial

VaccinationVaccine SafetyVaccinologyPhase 1/2ImmunologyVaccine EfficacyInfection ControlPolyvalent VaccineMedicineVaccine ResearchUs-based TrialHealthy Adults